CD19/22 Bi-specific CAR-T Cell Therapy
CD19/22 Bi-specific CAR-T Cells Targeting B Cell Malignancies
Shenzhen Geno-Immune Medical Institute
60 participants
Jun 30, 2022
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to assess the feasibility, safety and efficacy of anti-CD19/22 bi-specific CAR-T cell therapy in patients with CD19 and/or CD22 positive B cell malignancies. Another goal of the study is to learn more about the safety and function of the anti-CD19/22 bi-specific CAR-T cells and their persistency in patients.
Eligibility
Inclusion Criteria4
- age older than 6 months.
- malignant B cell surface expression of CD19 or CD22 molecules.
- the KPS score over 80 points, and survival time is more than 1 month.
- greater than Hgb 80 g/L.5. no contraindications to blood cell collection.
Exclusion Criteria4
- accompanied with other active diseases and difficult to assess patient response.
- bacterial, fungal, or viral infection, unable to control.
- living with HIV.4. active HBV or HCV infection.
- \. pregnant and nursing mothers. 6. under systemic steroid treatment within a week of the treatment. 7. prior failed CD19 and CD22 CAR-T treatment.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Infusion of bi-4SCAR CD19/22 T cells at 10\^6 cells/kg body weight via IV
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05432882